Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted therapy for BRAFV600E malignant astrocytoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Dec 2011

Nicolaides Theodore P, Li Huifang, Solomon David A, Hariono Sujatmi, Hashizume Rintaro, Barkovich Krister, Baker Suzanne J, Paugh Barbara S, Jones Chris, Forshew Tim, Hindley Guy F, Hodgson J Graeme, Kim Jung-Sik, Rowitch David H, Weiss William A, Waldman Todd A, James C David

Abstract excerpt

PURPOSE: Malignant astrocytomas (MA) are aggressive central nervous system tumors with poor prognosis. Activating mutation of BRAF (BRAF(V600E)) has been reported in a subset of these tumors, especially in children. We have investigated the incidence of BRAF(V600E) in additional pediatric patient cohorts and examined the effects of BRAF blockade in preclinical models of BRAF(V600E) and wild-type BRAF MA....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Kaplan-Meier Estimate

Share to Mice, Nude

Share to Sulfonamides

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 22038996
DOI: 10.1158/1078-0432.CCR-11-1456
PMCID: PMC3638050

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted therapy for BRAFV600E malignant astrocytoma.PMID 22038996Read ↗

Integrated molecular and clinical analysis of BRAF-mutant glioma in adultsSemantic proximity Read ↗

Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade GliomasSemantic proximity Read ↗

Cooperative interactions of BRAF <sup>V600E</sup> kinase and <i>CDKN2A</i> locus deficiency in pediatric malignant astrocytoma as a basis for rational therapySemantic proximity Read ↗

Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review.Semantic proximity Read ↗

Molecular Heterogeneity in BRAF-Mutant Gliomas: Diagnostic, Prognostic, and Therapeutic ImplicationsSemantic proximity Read ↗

Targeted Therapy for BRAF Mutant Brain Tumors.Semantic proximity Read ↗

Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.Semantic proximity Read ↗

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.Semantic proximity Read ↗

Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas.Semantic proximity Read ↗

Targeting BRAF in pediatric brain tumors.Semantic proximity Read ↗

The role of BRAF-targeted therapy in astrocytomas: a review.Semantic proximity Read ↗

Approaches toward improving the prognosis of pediatric patients with glioma: pursuing mutant drug targets with emerging small molecules.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.